OncoTherapy Science, Inc.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,135M | ¥610M | ¥750M | ¥809M |
| Gross Profit | ¥42M | -¥178M | -¥13M | ¥14M |
| Operating Income | -¥1,106M | -¥1,121M | -¥798M | -¥810M |
| Pretax Income | -¥1,116M | -¥1,285M | -¥812M | -¥907M |
| Net Income | -¥1,119M | -¥1,288M | -¥815M | -¥911M |
| EPS | -¥5.81 | -¥6.05 | -¥3.12 | -¥2.77 |
| Operating Margin | -97.49% | -183.70% | -106.38% | -100.23% |
| Balance Sheet | ||||
| Total Assets | ¥1,511M | ¥867M | ¥1,155M | ¥2,359M |
| Total Equity | ¥855M | ¥354M | ¥729M | ¥2,142M |
| Total Liabilities | ¥656M | ¥514M | ¥426M | ¥217M |
| Cash | ¥1,118M | ¥528M | ¥834M | ¥2,089M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 56.58% | 40.78% | 63.12% | 90.79% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥795M | -¥1,228M | -¥815M | -¥923M |
| Investing CF | -¥20M | -¥33M | -¥0M | -¥63M |
| Financing CF | ¥96M | ¥671M | ¥1,122M | ¥2,241M |
| Free CF | -¥800M | -¥1,231M | -¥815M | -¥985M |
| Efficiency | ||||
| ROE | -130.81% | -364.22% | -111.82% | -42.51% |
| ROA | -74.01% | -148.53% | -70.58% | -38.60% |
Latest IR Information
-
Q1 FY2027 Financial Results for the Fiscal Year Ending March 2027 (Japan GAAP) [Consolidated]
For the first quarter of the fiscal year ending March 2027, consolidated net sales were 170 million yen, operating loss was 285 million yen, ordinary loss was 287 million yen, and net loss attributable to owners of the parent was...
Read more -
Notice Regarding Monthly Exercise Status of the 38th Stock Acquisition Rights (with Exercise Price Adjustment Clauses) Issued via Third-Party Allotment
Read more -
Notice Regarding Membership Status and Our Approach to Joining the Public Benefit Organization for Financial Accounting Standards
Read more -
Business Plan and Growth Potential Matters
Read more -
Notice Regarding Large-Scale Exercise of the 38th Stock Acquisition Rights (with Exercise Price Adjustment Clause) through Third-Party Allotment
Reporting a large exercise of 38th stock acquisition rights. From June 1 to 9, 9,600,000 shares were issued, with 96,000 exercised (12.06% of total issued), and unexercised rights reduced to 150,000. Unexercised rights at the end of the previous month...
Read more
Latest News (5 items)
Company Information
About
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. The company's development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. Its pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, the company is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer's disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
